Showing 2221-2230 of 2314 results for "".
- National Cancer Institute Director Ned Sharpless to Become Acting FDA Headhttps://modernod.com/news/national-cancer-institute-director-ned-sharpless-to-cecome-acting-fda-head/2476373/Ned Sharpless, MD, the current director of the US National Cancer Institute (NCI), will assume the position of acting chief of the FDA when Scott Gottlieb, MD, steps down next month. Dr. Gottlieb, who recently tendered his resignation from the role, is said to have recommended Dr. Sharpless for t
- Aerie Pharmaceuticals Receives FDA Approval of Rocklatan for Reduction of IOPhttps://modernod.com/news/aerie-pharmaceuticals-receives-fda-approval-of-rocklatan-for-reduction-of-iop/2476371/Aerie Pharmaceuticals announced that the FDA has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily eye drop that is a fixed-dose combination of latan
- EyePoint Pharmaceuticals Announces US Commercial Launch of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-dexycu/2476370/EyePoint Pharmaceuticals announced that it has commercially launched Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as a single dose at the end
- Clemson Eye Integrates Two Greenville Eye Care Practices into Its Networkhttps://modernod.com/news/clemson-eye-integrates-two-greenville-eye-care-practices-into-its-network/2476368/This spring, Clemson Eye will unite with two Greenville eye health practices — Montgomery & Riddle Eyecare and Donelson Eye Associates — under the Clemson Eye brand name. Combined, the practices serve more than 100,000 patients and offer more than 10 specialties. “This transition is a
- Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCThttps://modernod.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/Zeiss announced that it has received FDA 510(k) clearance for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include epithelial thickness mapping (ETM). According to refractive specialist John Doane, MD, of Discover Vision Center in Kansas
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an
- Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasishttps://modernod.com/news/eyenovia-announces-confirmatory-results-from-second-microstat-phase-3-registration-study-for-mydriasis/2476266/Eyenovia announced positive results from its second MicroStat phase 3 study, MIST-2, which examined the safety and efficacy of the company’s first-in-class MicroStat fixed-combination formulation for pharmacologic mydriasis. The MIST-2 study was a US-based, multicenter, randomized, double-
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- ARISE-3 Phase 3 Clinical Trial of the RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTreehttps://modernod.com/news/arise-3-phase-3-clinical-trial-of-the-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/2476304/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora for the initiation of ARISE-3 to study the company’s new drug RGN-259 for the treatment of dry eye syndrome. ARISE-3 is a randomized, double masked, placebo cont
- Our Artificial Cornea Breakthrough Could Lead to Self-Assembling Organshttps://modernod.com/news/our-artificial-cornea-breakthrough-could-lead-to-self-assembling-organs/2476305/For every person in the world who receives a cornea transplant, there are 69 others who still need one. That leaves about 12.5m people with limited sight because there aren’t enough eye donors. But what if we cou